CC
ALNY icon

CQS Cayman’s Alnylam Pharmaceuticals ALNY Stock Holding History

CQS Cayman’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-134,780
Closed -$9.13M – 115
2016
Q3 		$9.13M Sell
134,780
-4,900
-4% -$346K 0.77% 38
2016
Q2 		$7.75M Buy
+139,680
New +$8.8M 0.68% 39

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman's ALNY Position: Q4 2016 in Review

CQS Cayman sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 134,780 shares — an estimated $9.13M sold.

CQS Cayman first reported a position in ALNY in Q2 2016 and held it in 2 quarters. The position peaked at $9.13M in Q3 2016. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • CQS Cayman reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • CQS Cayman sold 134,780 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $9.13M.
  • CQS Cayman first reported a position in Alnylam Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • CQS Cayman's Alnylam Pharmaceuticals position peaked at $9.13M in Q3 2016.
  • 210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on CQS Cayman's 13F filing for Q4 2016, filed 14 Feb 2017.